Robert Gagnon's most recent trade in Opus Genetics Inc. was a trade of 7,783 Common Stock done at an average price of $2.9 . Disclosure was reported to the exchange on July 23, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Opus Genetics Inc | Robert Gagnon | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.95 per share. | 23 Jul 2026 | 7,783 | 584,375 | - | 2.9 | 22,942 | Common Stock |
| Harvard Bioscience Inc | Robert Gagnon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2026 | 16,556 | 27,556 (0%) | 0% | 0 | Common Stock | |
| Opus Genetics Inc | Robert Gagnon | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 5.18 per share. | 23 Apr 2026 | 7,842 | 592,158 | - | 5.2 | 40,658 | Common Stock |
| Opus Genetics Inc | Robert Gagnon | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2026 | 400,000 | 600,000 | - | 0 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 16 Dec 2025 | 283 | 41,678 (0%) | 0% | 9.1 | 2,587 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 16 Sep 2025 | 281 | 41,961 (0%) | 0% | 10.0 | 2,807 | Common Stock | |
| Opus Genetics Inc | Robert Gagnon | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2025 | 250,000 | 250,000 | - | - | Employee Stock Option (right to buy) | |
| Opus Genetics Inc | Robert Gagnon | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2025 | 200,000 | 200,000 | - | 0 | Common Stock | |
| Harvard Bioscience Inc | Robert Gagnon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2025 | 110,000 | 110,000 (0%) | 0% | 0 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 16 Jun 2025 | 284 | 42,242 (0%) | 0% | 5.7 | 1,605 | Common Stock | |
| Bone Biologics Corp | Robert Gagnon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 62,894 | 62,894 | - | - | Non-Employee Stock Option | |
| Verastem Inc | Robert Gagnon | Director | 22 May 2025 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | ||
| Verastem Inc | Robert Gagnon | Director | 22 May 2025 | 8,333 | 42,526 (0%) | 0% | 0 | Common Stock | ||
| Verastem Inc | Robert Gagnon | Director | 17 Mar 2025 | 284 | 34,193 (0%) | 0% | 7.0 | 1,974 | Common Stock | |
| Verastem Inc | Gagnon Robert | Director | 16 Dec 2024 | 285 | 34,607 (0%) | 0% | 4.5 | 1,294 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 16 Dec 2024 | 130 | 34,477 (0%) | 0% | 4.4 | 568 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 19 Sep 2024 | 131 | 34,892 (0%) | 0% | 2.8 | 365 | Common Stock | |
| Bone Biologics Corp | Robert Gagnon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2024 | 30,713 | 30,713 | - | - | Non- Employee Stock Option | |
| Verastem Inc | Robert Gagnon | Director | 16 Sep 2024 | 287 | 35,023 (0%) | 0% | 2.8 | 804 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 17 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | ||
| Verastem Inc | Robert Gagnon | Director | 17 Jun 2024 | 8,333 | 35,441 (0%) | 0% | 0 | Common Stock | ||
| Verastem Inc | Robert Gagnon | Director | 17 Jun 2024 | 283 | 27,108 (0%) | 0% | 3.5 | 988 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 17 Jun 2024 | 131 | 35,310 (0%) | 0% | 3.2 | 421 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 18 Mar 2024 | 283 | 27,521 (0%) | 0% | 10.7 | 3,031 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 18 Mar 2024 | 130 | 27,391 (0%) | 0% | 10.4 | 1,349 | Common Stock | |
| Verastem Inc | Gagnon Robert | Director | 06 Feb 2024 | 9,204 | 27,804 (0%) | 0% | 13.7 | 126,095 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 12 Jan 2024 | 9,204 | 37,008 (0%) | 0% | 11.0 | 100,784 | Common Stock | |
| Bone Biologics Corp | Gagnon Robert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2024 | 9 | 9 | - | - | Non-Employee Stock Option | |
| Bone Biologics Corp | Robert Gagnon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2024 | 8 | 8,015 | - | - | Non-Employee Stock Option | |
| Verastem Inc | Gagnon Robert | Director | 18 Dec 2023 | 284 | 46,342 (0%) | 0% | 7.6 | 2,170 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 18 Dec 2023 | 130 | 46,212 (0%) | 0% | 7.7 | 1,005 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 16 Jun 2023 | 283 | 47,164 (0%) | 0% | 9.9 | 2,807 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 16 Jun 2023 | 130 | 47,034 (0%) | 0% | 10.3 | 1,339 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 15 May 2023 | 62,500 | 62,500 | - | - | Stock Option (right to buy) | ||
| Verastem Inc | Robert Gagnon | Director | 16 Mar 2023 | 3,654 | 571,063 (0%) | 0% | 0.4 | 1,462 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 16 Mar 2023 | 1,664 | 569,399 (0%) | 0% | 0.4 | 716 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 16 Dec 2022 | 12,408 | 576,146 (0%) | 0% | 0.4 | 4,963 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 16 Dec 2022 | 1,429 | 574,717 (0%) | 0% | 0.4 | 529 | Common Stock | |
| Verastem Inc | Robert Gagnon | Director | 13 Dec 2022 | 153,938 | 153,938 | - | - | Stock Option (right to buy) | ||
| Verastem Inc | Robert Gagnon | Chief Financial Officer | 19 Sep 2022 | 1,348 | 588,554 (0%) | 0% | 1.1 | 1,523 | Common Stock | |
| Verastem Inc | Robert Gagnon | Chief Financial Officer | 21 Jun 2022 | 1,351 | 589,902 (0%) | 0% | 1.1 | 1,540 | Common Stock | |
| Verastem Inc | Robert Gagnon | Chief Financial Officer | 14 May 2022 | 50,000 | 607,880 (0%) | 0% | 0 | Common Stock | ||
| Verastem Inc | Robert Gagnon | Chief Financial Officer | 14 May 2022 | 16,627 | 591,253 (0%) | 0% | 1.0 | 17,126 | Common Stock | |
| Verastem Inc | Robert Gagnon | Chief Financial Officer | 21 Mar 2022 | 1,409 | 557,880 (0%) | 0% | 1.3 | 1,789 | Common Stock | |
| Verastem Inc | Robert Gagnon | Chief Financial Officer | 03 Jan 2022 | 19,612 | 559,289 (0%) | 0% | 2.1 | 40,205 | Common Stock | |
| Verastem Inc | Robert Gagnon | Chief Financial Officer | 20 Dec 2021 | 5,497 | 578,901 (0%) | 0% | 2.3 | 12,478 | Common Stock | |
| Verastem Inc | Robert Gagnon | Chief Financial Officer | 12 Aug 2021 | 301,500 | 301,500 | - | - | Stock Option (Right to Buy) | ||
| Verastem Inc | Robert Gagnon | Chief Financial Officer | 12 Aug 2021 | 148,500 | 584,398 (0%) | 0% | 0 | Common Stock | ||
| Verastem Inc | Robert Gagnon | Chief Financial Officer | 12 Aug 2021 | 45,329 | 435,898 (0%) | 0% | 2.9 | 130,094 | Common Stock |